3,3′-Diindolylmethane Enhances Chemosensitivity of Multiple Chemotherapeutic Agents in Pancreatic Cancer
- 1 July 2009
- journal article
- retracted article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (13), 5592-5600
- https://doi.org/10.1158/0008-5472.can-09-0838
Abstract
Clinical management of pancreatic cancer is a major problem, which is in part due to both de novo and acquired resistance to conventional therapeutics. Here, we present in vitro and in vivo preclinical evidence in support of chemosensitization of pancreatic cancer cells by 3,3-diindolylmethane (DIM), a natural compound that can be easily obtained by consuming cruciferous vegetables. DIM pretreatment of pancreatic cancer cells led to a significantly increased apoptosis (P < 0.01) with suboptimal concentrations of chemotherapeutic agents (cisplatin, gemcitabine, and oxaliplatin) compared with monotherapy. It is known that resistance to chemotherapy in pancreatic cancer is associated with constitutively activated nuclear factor-κB (NF-κB), which becomes further activated by chemotherapeutic drugs. Our data provide mechanistic evidence for the first time showing that DIM potentiates the killing of pancreatic cancer cells by down-regulation of constitutive as well as drug-induced activation of NF-κB and its downstream genes (Bcl-xL, XIAP, cIAP, and survivin). Most importantly, using an orthotopic animal model, we found reduction in tumor size (P < 0.001) when DIM was given in combination with oxaliplatin compared with monotherapy. This was accompanied by loss of phospho-p65 and down-regulation of NF-κB activity and its downstream genes (Bcl-xL, survivin, and XIAP), which correlated with reduced cell proliferation (as assessed by Ki-67 immunostaining of tumor specimens) and evidence of apoptosis [as assessed by poly(ADP-ribose) polymease cleavage and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining]. These results provide strong in vivo evidence in support of our hypothesis that DIM could abrogate chemotherapeutic drug (cisplatin, gemcitabine, and/or oxaliplatin)–induced activation of NF-κB, resulting in the chemosensitization of pancreatic tumors to conventional therapeutics. [Cancer Res 2009;69(13):5592–600]Keywords
Other Versions
This publication has 50 references indexed in Scilit:
- Pharmacogenomic approach for the identification of novel determinants of acquired resistance to oxaliplatin in colorectal cancerMolecular Cancer Therapeutics, 2009
- Single-Dose Pharmacokinetics and Tolerability of Absorption-Enhanced 3,3′-Diindolylmethane in Healthy SubjectsCancer Epidemiology, Biomarkers & Prevention, 2008
- siRNA Directed Against Survivin Enhances Pancreatic Cancer Cell Gemcitabine ChemosensitivityDigestive Diseases and Sciences, 2008
- The Role of Nuclear Factor κB in Pancreatic Cancer and the Clinical Applications of Targeted TherapyPancreas, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Treatment of Advanced Pancreatic CancerSeminars in Oncology, 2007
- Retracted: In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancerInternational Journal of Cancer, 2006
- Cytotoxic Chemotherapy for Pancreatic CancerDrugs, 2006
- Mitogenic and antiapoptotic role of constitutive NF‐κB/Rel activity in pancreatic cancerInternational Journal of Cancer, 2003
- Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cellsZeitschrift für Krebsforschung und Klinische Onkologie, 2002